Global Paclitaxel Injection Market Research Report 2020
Paclitaxel Injection is a kind of anti-cancer injection taking paclitaxel API as raw material. It is mainly used in breast cancer, ovarian cancer and other cancers.
Paclitaxel injection comes as a liquid to be given intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given once every 3 weeks. When paclitaxel injection manufactured with polyoxyethylated castor oil is used to treat Kaposi's sarcoma, it may be given once every 2 or 3 weeks.
In recent years, the growing population and increasing disease incidence of ovarian cancer, breast cancer and other cancers drive the global paclitaxel injection industry developing.
In the past five years from 2010-2014, global paclitaxel injection industry developed fast with a larger than 15% annual production growth rate. In China, due to the late start, the production growth rate is 12%~17%, which is a little lower than global average.
In the next few years, with the growing attention on women cancers from the whole society and much larger investment on R&D of paclitaxel injection, this industry will continue developing at a high speed. What’s more, because of the high gross profit of producing and selling paclitaxel injection, more and more investors will enter into this industry.
At present, the production of paclitaxel injection mainly concentrated in US, China and EU, the three regions produced about 77.30% of the global total products. Of those, US are the largest production region with a 42.69% of global production market share.
In the future, with the expanded capacity of paclitaxel injection, the manufacturers will face the high risk of price and gross margin decline.
The global Paclitaxel Injection market is valued at 2720.1 million US$ in 2020 is expected to reach 5728.4 million US$ by the end of 2026, growing at a CAGR of 11.1% during 2021-2026.
This report focuses on Paclitaxel Injection volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Paclitaxel Injection market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan etc.
Market Segment Analysis
The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type, the Paclitaxel Injection market is segmented into
Drug Strength
Raw meterial Paclitaxel API source
Segment by Application
Ovarian cancer
Breast cancer
Cervical cancer
Pancreatic cancer
Other
Global Paclitaxel Injection Market: Regional Analysis
The Paclitaxel Injection market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
The key regions covered in the Paclitaxel Injection market report are:
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Global Paclitaxel Injection Market: Competitive Analysis
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
The major players in global Paclitaxel Injection market include:
Bristol-Myers Squibb
Celgene Corporation
Hospira
Biological E.
Taj Accura
Khandelwal Laboratories
Luye Pharma
Beijing Youcare
Beijing Union
Haiyao
Chuntch
Paclitaxel injection comes as a liquid to be given intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given once every 3 weeks. When paclitaxel injection manufactured with polyoxyethylated castor oil is used to treat Kaposi's sarcoma, it may be given once every 2 or 3 weeks.
In recent years, the growing population and increasing disease incidence of ovarian cancer, breast cancer and other cancers drive the global paclitaxel injection industry developing.
In the past five years from 2010-2014, global paclitaxel injection industry developed fast with a larger than 15% annual production growth rate. In China, due to the late start, the production growth rate is 12%~17%, which is a little lower than global average.
In the next few years, with the growing attention on women cancers from the whole society and much larger investment on R&D of paclitaxel injection, this industry will continue developing at a high speed. What’s more, because of the high gross profit of producing and selling paclitaxel injection, more and more investors will enter into this industry.
At present, the production of paclitaxel injection mainly concentrated in US, China and EU, the three regions produced about 77.30% of the global total products. Of those, US are the largest production region with a 42.69% of global production market share.
In the future, with the expanded capacity of paclitaxel injection, the manufacturers will face the high risk of price and gross margin decline.
The global Paclitaxel Injection market is valued at 2720.1 million US$ in 2020 is expected to reach 5728.4 million US$ by the end of 2026, growing at a CAGR of 11.1% during 2021-2026.
This report focuses on Paclitaxel Injection volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Paclitaxel Injection market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan etc.
Market Segment Analysis
The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type, the Paclitaxel Injection market is segmented into
Drug Strength
Raw meterial Paclitaxel API source
Segment by Application
Ovarian cancer
Breast cancer
Cervical cancer
Pancreatic cancer
Other
Global Paclitaxel Injection Market: Regional Analysis
The Paclitaxel Injection market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
The key regions covered in the Paclitaxel Injection market report are:
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Global Paclitaxel Injection Market: Competitive Analysis
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
The major players in global Paclitaxel Injection market include:
Bristol-Myers Squibb
Celgene Corporation
Hospira
Biological E.
Taj Accura
Khandelwal Laboratories
Luye Pharma
Beijing Youcare
Beijing Union
Haiyao
Chuntch
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
